Engineered immune cells aim to tame childhood autoimmune diseases
NCT ID NCT06792799
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new type of cell therapy (CAR-NK cells) in 36 children with B-cell-related autoimmune diseases like lupus and certain kidney diseases. The therapy uses specially designed immune cells to target and potentially control the overactive immune system. The main goals are to check if the treatment is safe and if it can reduce disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-CD19/BCMA CAR NK cells (KN5601)
What this could lead to
If successful, this could point toward a new treatment option for children with severe autoimmune diseases like lupus or kidney disease that don't respond to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 36 participants, so safety and effectiveness are not yet proven. There are risks from the chemotherapy given before the cell infusion and from the cells themselves, including serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000
RECRUITINGHangzhou, Zhejiang, 310052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact